MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$11,413K
Free Cash flow
-$17,599K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities/sales of short-term i...
Stock-based compensation expense
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Accrued liabilities
Accounts payable
Operating lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-14,387
-21,588
-17,598
-16,316
Credit loss - related party accounts receivable
-
-
0
0
Stock-based compensation expense
1,950
2,004
1,581
1,500
Non-cash lease expense
89
86
84
83
Unrealized loss on short-term investments
2
-13
-19
36
Amortization of discount on short-term investments
19
118
233
372
Depreciation expense
11
11
10
10
Prepaid expenses and other assets
-146
333
369
1,313
Accounts payable
-2,407
2,421
-2,372
-612
Accrued liabilities
-2,875
-1,260
2,172
1,026
Operating lease liability
-105
-105
-104
-100
Net cash used in operating activities
-17,599
-18,869
-16,810
-16,130
Purchases of short-term investments
0
0
4,948
0
Maturities/sales of short-term investments
28,750
34,250
29,250
29,250
Purchases of property and equipment
0
-
0
4
Net cash provided by (used in) investing activities
28,750
34,250
24,302
29,246
Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts
0
0
0
0
Financing costs paid in connection with initial public offering
0
0
0
0
Proceeds from sale and issuance of series c convertible preferred stock
-
-
0
0
Proceeds from issuance of common stock under employee stock purchase plan
259
-
195
-
Financing costs paid in connection with issuance of series c convertible preferred stock
-
-
0
0
Costs paid in connection with deferred financing costs
-
-
0
-
Proceeds from exercises of common stock options
3
4
79
171
Net cash provided by financing activities
262
4
274
171
Net increase (decrease) in cash and cash equivalents
11,413
15,385
7,766
13,287
Cash and cash equivalents at beginning of period
62,436
47,051
39,285
61,641
Cash and cash equivalents at end of period
73,849
62,436
47,051
39,285
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities/sales of short-term
investments
$28,750K
(33.55%↑ Y/Y)
Proceeds from issuance of
common stock under...
$259K
Proceeds from exercises
of common stock...
$3K
(-97.41%↓ Y/Y)
Net cash provided by
(used in) investing...
$28,750K
(127.85%↑ Y/Y)
Net cash provided by
financing activities
$262K
(-99.70%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$11,413K
(132.02%↑ Y/Y)
Canceled cashflow
$17,599K
Stock-based compensation
expense
$1,950K
(124.91%↑ Y/Y)
Prepaid expenses and
other assets
-$146K
(-103.41%↓ Y/Y)
Non-cash lease expense
$89K
(-58.22%↓ Y/Y)
Depreciation expense
$11K
(-31.25%↓ Y/Y)
Net cash used in
operating activities
-$17,599K
(17.11%↑ Y/Y)
Canceled cashflow
$2,196K
Net loss
-$14,387K
(39.24%↑ Y/Y)
Accrued liabilities
-$2,875K
(-189.37%↓ Y/Y)
Accounts payable
-$2,407K
(-174.68%↓ Y/Y)
Operating lease liability
-$105K
(21.64%↑ Y/Y)
Amortization of discount on
short-term investments
$19K
(-97.29%↓ Y/Y)
Unrealized loss on
short-term investments
$2K
(109.09%↑ Y/Y)
Buy us a coffee
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)